The Catalyst Clinic: The Science of Age-less Living

Dr. Ethan Hausman-Marquis
  • 2.3 (3)
  • Medicine

Welcome to The Science of Age-Less Living ! Dr. Ethan Hausman-Marquis—logevity researcher, biohacker and founder of The Catalyst Clinic—shares his journey into the fields of aesthetics, regenerative medicine, and longevity science, and offers a look at what the future of aging may hold. From his early studies at UCLA to advanced work in genomics and molecular biology at L’École Normale Supérieure in Paris and a PhD at the Karolinska Institute in Stockholm, Dr. Ethan’s path has been guided by one goal: helping people live longer, healthier, and more vibrant lives. He is the author of Exploring the World of Peptides: From Basics to Breakthroughs and Peptide-Based Cancer Therapies: A New Frontier in Precision Medicine, and has contributed to several peer-reviewed publications on cutting-edge medical research. In this episode, Dr. Ethan reflects on his transition from academic research to clinical innovation at The Catalyst Clinic—with locations in London, New York, Amsterdam, and soon Zürich—and sets the stage for what’s to come in future episodes. Each week, The Science of Age-Less Living explores the molecular and cell biology of longevity—the evolving landscape of regenerative medicine, the power of peptides, the genetics of aging, and the simple, practical tools that can help you thrive at any age. Join us as we explore what it truly means to age well—combining science, medicine, and mindset to help you live not just longer, but better. Let’s begin the journey to Age-Less Living. Learn more at: thecatalystclinic.com/wellness/peptide-therapy

  1. Oct 25

    Why Aren’t We Age-less? The Molecular Receipt for Being Young

    This episode Dr Ethan asks a deceptively simple question — why do we age and die on a predictable schedule? — and answers it by weaving together molecular biology and evolutionary theory. It opens by dismantling the myth that ancient humans never grew old (a distortion caused by averaging in high child mortality), showing via Gompertz’s 1825 mortality curve that adult death risk doubles on a fixed interval of roughly eight years. It then traces the discovery that aging is written partly into our cells: Carrel’s seemingly immortal chicken-heart culture, overturned by Hayflick’s finding that normal human cells divide about fifty times and then enter senescence — a state enforced by the cell-cycle brakes p16 (CDKN2A) and p21 (CDKN1A) and broadcast through the NF-κB-driven inflammatory SASP, contributing to “inflammaging.” The molecular thread continues with telomeres — the TTAGGG caps that shorten each division because DNA polymerase can’t copy the very end of a strand — and the enzyme telomerase (TERT/TERC) that can rebuild them. The twist is that the body keeps telomerase switched off in most cells as an anti-cancer safeguard, since ~90% of tumours reactivate it. The same logic governs p53 (TP53), the “guardian of the genome”: the 2002 Houston mouse experiment showed that extra p53 cut cancer but accelerated aging, the clearest real example of antagonistic pleiotropy — a gene that protects the young at the cost of the old. The episode then shifts to evolutionary explanations: Medawar’s selection shadow (late-acting harmful genes escape selection because few ancestors lived long enough to suffer them), Williams’s trade-off principle, and Kirkwood’s disposable soma theory. Finally, the predictions are tested in the wild — Austad’s longer-lived predator-free Sapelo Island opossums, long-lived bats and naked mole rats — and in our own past, where Caspari’s wisdom-tooth analysis shows a surge in humans reaching grandparent age ~30,000 years ago, tied to safer living and the grandmother hypothesis. The conclusion unifies all four clues: selection buys protection for the young, and danger sets how much it spends on the old. The host closes on the experimental frontier of senolytics — compounds targeting the BCL-2 survival proteins (fisetin, dasatinib-plus-quercetin, FOXO4–p53-disrupting peptides) — with an explicit caveat that none are approved anti-aging therapies and that the honest stance is hope without hype.

    Why Aren’t We Age-less? The Molecular Receipt for Being Young

  2. Oct 9

    Uncovering the Science of Age-less Living: The Catalyst Method

    Most people in the longevity space run the process backward. They pick the compound first, then look for the problem it solves, and by the time anyone measures anything there's no baseline left to measure against. In this episode, Dr. Ethan Hausman-Marquis lays out The Catalyst Method — the rule that governs everything at The Catalyst Clinic: no data, no protocol. He walks through the full diagnostic panel, from the growth-hormone axis and metabolic markers to ApoB, Lp(a), thyroid antibodies, and full iron studies, and explains what each one is actually protecting against. The argument is blunt: two patients with identical symptoms, identical age, and identical goals can need opposite things, and the only thing that tells them apart is a number. The second half turns to genetics, and to a distinction that rarely gets made out loud. Pharmacogenomics — how you metabolize what you're given — has published prescribing guidelines and changes decisions today. Monogenic risk findings like familial hypercholesterolemia change what you screen for and when, and often change outcomes for an entire family. But the sprawling wellness SNP panel is a different product with a different evidence base, and Ethan says so directly, along with the rule he applies to every test he orders: if a result won't change a decision, he shouldn't be charging for it. He also makes an on-air correction to how this topic is discussed across the industry, including by him. Four composite cases close the episode: the executive whose baseline panel stopped a protocol before it started, the patient whose supplement shelf was quietly injuring her, the woman who spent years labeled "statin intolerant" over a single transporter variant, and the asymptomatic thirty-one-year-old whose lipid panel ended up putting three family members on treatment. Also covered: AURION, the system the clinic built to hold a hundred-plus data points in one view, and a clear account of what it does and doesn't decide.

    Uncovering the Science of Age-less Living: The Catalyst Method

  3. Oct 8

    The Age-less Edge: Can Science Actually Rejuvenate Your Immune System?

    Your immune system doesn't age at the same rate as the rest of you — and that gap might matter more than your birthday. In this episode, Dr. Ethan Hausman-Marquis breaks down the three biological processes driving immune decline (a shrinking supply of new T cells, a growing population of "exhausted" T cells worn down by years of repeated activation, and the chronic low-grade inflammation that results) and explains why two people of the same chronological age can have wildly different immune resilience. The episode centers on a real, recently announced UCL trial from biotech spinout SenTcell, which is preparing a first-in-human Phase 1 study aiming to metabolically reprogramme exhausted T cells back toward youthful function. Dr. Ethan walks through exactly what the trial can and can't tell us at this stage, draws a credible parallel to already-approved cancer immunotherapies that work on similar biology, and is upfront about the realistic decade-long runway between early trial and approved treatment. Rather than stop at the hype, the episode spends real time on the open questions: could reactivating exhausted T cells tip some people toward autoimmunity, the way it sometimes does with checkpoint inhibitors? What's actually within listeners' control today — sleep, visceral fat, chronic stress, viral exposure — while the science matures? And what does "success" even mean here: not living forever, but preserving the ability to fight disease for longer.

    The Age-less Edge: Can Science Actually Rejuvenate Your Immune System?

  4. Sep 21

    The Age-Less Advantage: Why Muscle Is Your Body's Longevity Organ

    Most people file muscle under "fitness" — something for the gym, something for looking a certain way. This episode makes the case for a different framing: skeletal muscle functions as an endocrine organ, releasing signaling proteins called myokines that regulate blood sugar, dampen chronic inflammation, and support bone density. Dr. Ethan breaks down why losing muscle — a process called sarcopenia — doesn't just cost you strength, it accelerates metabolic disease, frailty, and fall risk, and why a simple five-second grip-strength test may predict your mortality risk as well as many of the biomarkers your annual physical actually checks. Dr. Ethan also gets personal, drawing on his own experience as a competitive bodybuilder to explain what maintaining significant muscle mass over years has taught him clinically: that holding onto muscle as you age is active work, not a default state, and that the discipline required to protect it — while far less intense than competitive training — has to be repeated and specific. The episode closes with a concrete, no-supplement protocol: two resistance training sessions a week, daily non-exercise movement, protein at every meal, protected sleep, and social connection — and an argument for why this unglamorous combination likely outperforms most of the trending biohacks currently dominating the longevity conversation.

    The Age-Less Advantage: Why Muscle Is Your Body's Longevity Organ

  5. Aug 8

    Age-less by Design: The Centenarian Genes That Rewrite How We Grow Old

    What separates someone managing a pharmacy's worth of medications at seventy-five from someone who's just getting started on the road to a hundred and two? In this episode, we crack open the biological instruction manual of the world's centenarians and read its most remarkable pages. We start with a crucial distinction — the difference between lifespan (how long you live) and healthspan (how long you live well) — and the striking pattern researchers call the compression of morbidity: the way the very longest-lived people tend to stay healthy far longer and then decline quickly, burning clean and steady rather than guttering out over decades. From there, we tour the genes that show up again and again in centenarian studies across the globe. We meet APOE, the double-edged gene whose different versions tilt the odds toward risk or protection; FOXO3, the "building superintendent" that switches on your cells' repair, cleanup, and recycling crews; and the counterintuitive growth paradox of IGF-1 and mTOR, where dialing down the body's relentless "grow!" signal turns out to favor a longer, more durable life. We round out the cast with Klotho, the DNA-repair scribes that keep your genetic manuscript faithful over a lifetime, and the immune-signaling genes that know when to stand inflammation down instead of letting it smolder into "inflammaging." But the real payoff isn't a list of genes you either have or don't. It's the single idea underneath all of them: genetics loads the gun, but lifestyle pulls the trigger. Many of the exact pathways centenarians inherit for free — maintenance, repair, restraint, regulation — have handles that your daily choices can reach, through movement, sleep, the rhythm of eating, and managing chronic inflammation. You can't swap your DNA, but you can influence which genes are switched on and how loudly. This episode is about learning where those dimmer switches are, and why aging age-lessly was never a locked door.

    Age-less by Design: The Centenarian Genes That Rewrite How We Grow Old

  6. Aug 3

    The Age-less Night: How Your Pineal Gland Rewrites Your Genes While You Sleep

    Most people treat sleep as simple recovery, but this episode reframes it as the nightly window in which a gland smaller than a pea helps decide how fast you age. That gland is the pineal gland, buried at the center of your brain, and its job is to release melatonin — not really a "sleep chemical" but a darkness signal that tells every cell in your body it's night. This signal is wired to light hitting your eyes and routed through your brain's master clock, the SCN. The catch: the pineal gland tends to calcify and its melatonin output declines with age, so the darkness signal that once washed cleanly through your body every night grows quieter over the decades. That fading signal matters because you don't have one clock — you have trillions. Nearly every cell runs its own roughly-24-hour rhythm built from "clock genes," and those genes control the timing of a huge share of what your body does, from DNA repair to metabolism to immune activity. Melatonin helps keep all these clocks synchronized. When chronic stress and poor sleep scramble that synchronization, gene expression shifts: the inflammation program (driven by NF-κB) creeps on, while repair-and-protection systems tied to the clock — like the longevity-linked SIRT1 — get thrown off schedule. Crucially, none of this mutates your DNA; it changes which genes are switched on and off through epigenetic "bookmarks" that respond to how you live. The hopeful takeaway is that because these are shifts in gene expression rather than permanent damage, much of it responds to daily behavior. The episode's highest-leverage moves are unglamorous and free: get bright light into your eyes early in the morning, defend real darkness in the hour before bed, keep your sleep timing consistent, and wind down evening stress so your cortisol rhythm stays intact. Melatonin supplements are framed honestly as a timing tool, not a proven anti-aging cure. The through-line is the show's core promise — that the most powerful levers on aging are often the quietest ones you already control.

    The Age-less Night: How Your Pineal Gland Rewrites Your Genes While You Sleep

  7. Jul 26

    The Age-Less Off-Ramp: What Happens When You Stop GLP-1s

    The GLP-1 receptor agonists are the most effective weight loss agents ever brought to market, and their efficacy is entirely contingent on continued administration. Three randomized withdrawal studies across two molecules make this unambiguous: the STEP-1 extension found participants regained roughly two-thirds of their lost weight within a year of stopping, with blood pressure, lipids, glycaemia and inflammatory markers reverting alongside it. STEP-4 and SURMOUNT-4 showed the same pattern under cleaner designs, with the gap between continuing and stopping running to fifteen percentage points of body weight in under a year. The science of getting onto these drugs is mature. The science of getting off them is roughly a decade behind. This episode explains why, and the answer is physiological rather than behavioral. Weight loss of any kind provokes a coordinated defense — leptin falls disproportionately, ghrelin rises above pre-treatment levels, satiety peptides decline, and energy expenditure adapts downward — and that response persists for at least a year. Throughout treatment, the drug doesn't resolve this counter-regulation; it masks it by agonizing the same receptors the system uses to signal satiety. Withdraw the drug and what emerges isn't the patient's old appetite. It's the unopposed appetite of a person who has just lost fifteen percent of their body weight. Compounding this is an asymmetry in body composition: lean tissue is lost readily and regained poorly, so a completed cycle returns the patient to their starting weight with a worse ratio — a trajectory that runs directly counter to healthy aging. We work through the pharmacology properly — albumin-binding, hypothalamic melanocortin signaling, dual GIP/GLP-1 agonism, the mesolimbic reward effects — then take the off-ramp strategies one at a time and label the evidence for each honestly: chronic therapy, maintenance dosing, tapering, bridging technologies like Fractyl's duodenal resurfacing, and the next-generation oral and triple agonists. Most of what is currently done in clinical practice rests on mechanistic reasoning rather than trial data, and the distinction matters. The conclusion is straightforward: these drugs are a chronic therapy for a chronic condition, not a course of treatment, and anyone presenting them as a finite intervention with a permanent result is either not reading the withdrawal trials or choosing not to mention them.

    The Age-Less Off-Ramp: What Happens When You Stop GLP-1s

  8. Jul 17

    Age-less or Overhyped? The Sixty-Year Cerebrolysin Puzzle | The Age-Less Top 20 Peptides

    Episode summary Cerebrolysin is a peptide preparation with a strange résumé: developed in Austria more than sixty years ago, approved in nearly fifty countries for stroke, traumatic brain injury, and dementia, put through hundreds of clinical trials — and yet still surrounded by a genuinely unresolved question about whether it works. In this episode we unpack what it actually is (not a single peptide, but a standardized mixture of amino acids and small fragments made by enzymatically digesting pig brain tissue), the one clever idea at its core (fragments small enough to slip across the blood-brain barrier and mimic the brain's own neurotrophic factors like BDNF and NGF), and the crucial gap between an effect in a lab dish and a real benefit in a human being. Then we get to the part the marketing skips. A 2023 systematic review found Cerebrolysin likely offers no benefit for survival in acute ischemic stroke and may even raise the rate of serious adverse events — and much of the supportive research has been funded by the manufacturer. We also cover the uncomfortable reality behind the vials sold online: it's not FDA-approved in the US, and the "research use only" label is a legal workaround for shipping an unregulated injectable with no purity or sterility guarantees. The takeaway is neither hype nor dismissal — Cerebrolysin is a genuinely interesting compound aimed at a real target, but the honest evidence says it's worth watching, not worth self-experimenting on with a needle. As always: not medical advice, and a real conversation for a licensed physician.

    Age-less or Overhyped? The Sixty-Year Cerebrolysin Puzzle | The Age-Less Top 20 Peptides
See All (50)

2.3
out of 5
3 Ratings

About

Welcome to The Science of Age-Less Living ! Dr. Ethan Hausman-Marquis—logevity researcher, biohacker and founder of The Catalyst Clinic—shares his journey into the fields of aesthetics, regenerative medicine, and longevity science, and offers a look at what the future of aging may hold. From his early studies at UCLA to advanced work in genomics and molecular biology at L’École Normale Supérieure in Paris and a PhD at the Karolinska Institute in Stockholm, Dr. Ethan’s path has been guided by one goal: helping people live longer, healthier, and more vibrant lives. He is the author of Exploring the World of Peptides: From Basics to Breakthroughs and Peptide-Based Cancer Therapies: A New Frontier in Precision Medicine, and has contributed to several peer-reviewed publications on cutting-edge medical research. In this episode, Dr. Ethan reflects on his transition from academic research to clinical innovation at The Catalyst Clinic—with locations in London, New York, Amsterdam, and soon Zürich—and sets the stage for what’s to come in future episodes. Each week, The Science of Age-Less Living explores the molecular and cell biology of longevity—the evolving landscape of regenerative medicine, the power of peptides, the genetics of aging, and the simple, practical tools that can help you thrive at any age. Join us as we explore what it truly means to age well—combining science, medicine, and mindset to help you live not just longer, but better. Let’s begin the journey to Age-Less Living. Learn more at: thecatalystclinic.com/wellness/peptide-therapy

Information

You Might Also Like